These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 27474481)

  • 1. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.
    González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V
    Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypill Strategy in Secondary Cardiovascular Prevention.
    Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
    N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
    Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
    An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study.
    Megiddo I; Chatterjee S; Nandi A; Laxminarayan R
    Glob Heart; 2014 Dec; 9(4):391-398.e3. PubMed ID: 25592792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
    Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP
    Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.